Advanta Dx SARS-CoV-2 RT-PCR Assay
Fluidigm has developed a diagnostic molecular test for the qualitative detection of SARS-CoV-2 in saliva specimens and has filed for FDA Emergency Use Authorization (EUA).
The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm's proprietary microfluidics technology and Juno™ and Biomark™ HD systems, enables high throughput and scalable testing of saliva samples from patients suspected of COVID-19 (coronavirus) infection. Featuring extraction-free sample processing, a modular workflow and large batch-sample size, the Advanta Dx SARS-CoV-2 RT-PCR Assay could enhance laboratory testing capacity while providing reliable results to support clinical decision making.Test Platform Highlights
- Extraction free: No need for viral RNA extraction kit
- High throughput: 192 samples and controls per batch in less than 3 hours of instrument time
- Scalable: Modular platform supports concurrent parallel runs to achieve up to 6,000 samples and controls/day/instrument.
- Noninvasive: Saliva collection is convenient, stress-free and pain-free.
Links to CDC Guidelines
Download the Advanta Dx SARS-CoV-2 RT-PCR Assay flyer.
Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a real-time Reverse Transcription (RT)PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in saliva specimens from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to Laboratories - certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in saliva during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administration’s Emergency Use Authorization.
“There’s an urgent need to simplify testing for COVID-19 so that people who are infected can be easily and quickly identified. The test we developed in collaboration with Fluidigm doesn’t require RNA extraction, a time-consuming and expensive step necessary to other tests for SARS-CoV-2. Our test could be easily scaled up and made widely available.”
Director of the Genome Technology Access Center at the McDonnell Genome Institute
The Advanta Dx SARS-CoV-2 RT-PCR Assay is a real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in saliva specimens from individuals suspected of COVID-19 by their health care provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high-complexity tests. See complete Intended Use and additional information in the Instructions for Use (FLDM-00161).
Information in this publication is subject to change without notice. Patent and license information: fluidigm.com/legal/notices.
Trademarks: Fluidigm, the Fluidigm logo, Advanta, Biomark and Juno are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.
©2020 Fluidigm Corporation. All rights reserved. 07/2020